Piper Jaffray analyst David Amsellem maintained a Hold rating on Teva Pharmaceutical Industries (TEVA – Research Report) today and set a price target of $7.00. The company’s shares closed last Monday at $8.85, close to its 52-week low of $6.07.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -0.2% and a 46.1% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Bausch Health Companies, and Adamas Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Teva Pharmaceutical Industries with a $8.50 average price target, representing a -0.4% downside. In a report issued on October 29, RBC Capital also maintained a Hold rating on the stock with a $8.00 price target.
The company has a one-year high of $24.47 and a one-year low of $6.07. Currently, Teva Pharmaceutical Industries has an average volume of 20.95M.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.